Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BILR 355 + ritonavir
- Development stage
- Discontinued
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BILR 355 + ritonavir is a fixed-dose combination of the investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) **BILR 355** and the protease inhibitor **ritonavir**. BILR 355 is a potent NNRTI developed for the treatment of HIV-1 infection, including forms resistant to first-generation NNRTIs. Ritonavir is co-administered at low doses as a pharmacokinetic enhancer (“booster”) due to its inhibition of the cytochrome P450 3A4 (CYP3A4) enzyme, thereby increasing systemic exposure of BILR 355 and prolonging its half-life. The combination is studied in both treatment-naïve and NNRTI-experienced HIV-infected patients, but BILR 355 is considered investigational and has not advanced to late-phase development or approval.
- Other names
- BILR 355/r
02
Targets
CYP3A4 (Cytochrome P450 3A4)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on BILR 355 + ritonavir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BILR 355 + ritonavir.